Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Deepa Rangachari, M.D.

Co-Author

This page shows the publications co-authored by Deepa Rangachari and Kartik Sehgal.
Connection Strength

3.490
  1. Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic? Front Oncol. 2020; 10:1193.
    View in: PubMed
    Score: 0.904
  2. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2021 05; 22(3):e379-e389.
    View in: PubMed
    Score: 0.901
  3. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. JAMA Netw Open. 2021 02 01; 4(2):e2037120.
    View in: PubMed
    Score: 0.236
  4. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist. 2021 04; 26(4):281-287.
    View in: PubMed
    Score: 0.231
  5. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.226
  6. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? Precis Cancer Med. 2020 Jun; 3.
    View in: PubMed
    Score: 0.226
  7. Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer? Transl Lung Cancer Res. 2019 Oct; 8(5):715-722.
    View in: PubMed
    Score: 0.215
  8. Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. Transl Cancer Res. 2018 Aug; 7(Suppl 7):S779-S786.
    View in: PubMed
    Score: 0.198
  9. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. J Thorac Oncol. 2019 01; 14(1):e1-e3.
    View in: PubMed
    Score: 0.197
  10. Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clin Res Rep. 2020 Nov; 1(4):100074.
    View in: PubMed
    Score: 0.057
  11. Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer. J Thorac Oncol. 2019 02; 14(2):e34-e36.
    View in: PubMed
    Score: 0.051
  12. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 07; 13(7):1037-1042.
    View in: PubMed
    Score: 0.048
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.